Bosutinib, a dual Src/Abl kinase inhibitor, has shown potent activity against chronic myeloid leukemia (CML). This phase I/II study evaluated bosutinib in patients with chronic phase imatinib-resistant or imatinib-intolerant CML. read more http://bloodjournal.hematologylibrary.org/content/early/2011/08/24/blood-2011-05-355594.abstract